Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis (BUTEO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02239211
Recruitment Status : Completed
First Posted : September 12, 2014
Last Update Posted : May 3, 2019
Sponsor:
Collaborators:
Biotie Therapies Corp.
University Hospital Birmingham
National Institute for Health Research, United Kingdom
Information provided by (Responsible Party):
University of Birmingham

Tracking Information
First Submitted Date  ICMJE September 4, 2014
First Posted Date  ICMJE September 12, 2014
Last Update Posted Date May 3, 2019
Actual Study Start Date  ICMJE September 8, 2015
Actual Primary Completion Date October 23, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 30, 2019)
Response at Visit 10 (Day 99): a reduction in serum ALP by 25% or more from baseline to Visit 10 (Day 99) [ Time Frame: 99 days ]
Original Primary Outcome Measures  ICMJE
 (submitted: September 10, 2014)
  • To determine the activity of the anti-Vap-1 antibody BTT1023 in patients with PSC as measured by a decrease in alkaline phosphatase levels (primary endpoint) with secondary endpoints to include various measures of liver injury and fibrosis. [ Time Frame: 99 days ]
    Vap-1 levels will be measured at multiple times from initiation of treatment, during treatment (78 days) and post treatment.
  • To evaluate the safety and tolerability of BTT1023 in patients with PSC [ Time Frame: 120 days ]
    Biochemical blood tests will be measured throughout the study period, as well as additional cardiology assessments (ECG). The results of these tests will be contribute to the safety evaluation of BTT1023.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 30, 2019)
  • Treatment Compliance (including patient withdrawal) [ Time Frame: 120 days ]
    These will be measured to evaluate the tolerability of BTT1203 in patients with PSC
  • Serious Adverse Event (SAE) frequency [ Time Frame: 120 days ]
    These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC
  • Adverse Event (AE) frequency [ Time Frame: 120 days ]
    These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire EQ-5D [ Time Frame: 99 days ]
    Using validated EQ-5D scoring system
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Fatigue Severity Scale [ Time Frame: 99 days ]
    The scoring is done by calculating the average response to the questions (adding up all the answers and dividing by nine).
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Pruritus Visual Analogue Score [ Time Frame: 99 days ]
    VAS measured as per guidelines
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Inflammatory Bowel Disease Diaries (if applicable) [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in enhanced liver fibrosis test [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Fibroscan measures [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Aspartate Transaminase (AST) [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Alanine Transaminase (ALT) [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Alkaline Phosphatase (ALP) [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Gamma Glutamyl Transferase (GGT) [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Bilirubin [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Albumin [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in International Normalised Ratio (INR) [ Time Frame: 99 days ]
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Mayo PSC Risk Score [ Time Frame: 99 days ]
    PSC Risk score calculated as per The Revised Natural History Model for Primary Sclerosing Cholangitis
  • Calculation of any change (improvement or worsening) from baseline to Day 99 in Model for End Stage Liver Disease (MELD) Score [ Time Frame: 99 days ]
    MELD calculated as per pre 2016 guidelines
  • Evaluate changes (improvement or worsening) in sVAP-1/SSAO as a biomarker of liver disease activity across the trial period [ Time Frame: 120 days ]
Original Secondary Outcome Measures  ICMJE
 (submitted: September 10, 2014)
  • To determine the mechanisms of action of BTT1023 through in vivo assessment of SSAO enzyme activity and immune cell function. [ Time Frame: 120 days ]
    SSAO and immune cell assay function will be performed throughout the entire period.
  • To evaluate the potential of a novel MRI based assessment of liver fibrosis and biliary strictures for assessing therapeutic outcome in PSC. [ Time Frame: Baseline and day 120 ]
    MRI imaging of the liver will be performed at two time points (baseline, day 120). This imaging will be assessed using a novel analytical method.
  • Assess the use of sVap-1 as a biomarker to monitor disease progression in PSC. [ Time Frame: 120 days ]
    Multiple measures of the known potential biomarker (sVAP-1) wiil be taken and correlated against clinical outcome throughout the period of the trial.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
Official Title  ICMJE A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).
Brief Summary This is a phase II study to determine the safety and preliminary efficacy of a human monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use in the treatment of patients with primary sclerosing cholangitis (PSC).
Detailed Description

Primary sclerosing cholangitis is a progressive immune mediated biliary disease characterised by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis. For patients with elevated alkaline phosphatase (ALP) in particular, progressive disease is predicted, that currently results in a need for liver transplantation in the majority. No current medical therapy has as yet been shown to be effective in altering the natural history of disease. For this reason patients with PSC with elevated ALP values will be recruited to this study, to evaluate the impact of Vap-1 blockade by BTT1023, in an early phase study focused on biochemical efficacy and safety.

This is an early phase study of BTT1023 in immune mediated liver disease, with the rationale to identify biochemical efficacy of effect (reduction in ALP) and safety, in an orphan disease indication for PSC that presently lacks any other medical therapy. The study design therefore focuses on identifying early biochemical efficacy signals to justify larger scale, randomised controlled studies over longer duration.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Primary Sclerosing Cholangitis
Intervention  ICMJE Drug: BTT1023
IV (in the vein) Investigational Medicinal Product (IMP)
Study Arms  ICMJE Experimental: BTT1023
BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
Intervention: Drug: BTT1023
Publications * Arndtz K, Corrigan M, Rowe A, Kirkham A, Barton D, Fox RP, Llewellyn L, Athwal A, Wilkhu M, Chen YY, Weston C, Desai A, Adams DH, Hirschfield GM; BUTEO trial team. Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. BMJ Open. 2017 Jul 3;7(6):e015081. doi: 10.1136/bmjopen-2016-015081.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 30, 2019)
23
Original Estimated Enrollment  ICMJE
 (submitted: September 10, 2014)
41
Actual Study Completion Date  ICMJE October 23, 2018
Actual Primary Completion Date October 23, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females 18 - 75 years of age who are willing and able to provide informed, written consent and comply with all trial requirements
  2. Clinical diagnosis of PSC as evident by chronic cholestasis of more than six months duration with either a consistent MRI showing sclerosing cholangitis or a liver biopsy consistent with PSC in the absence of a documented alternative aetiology for sclerosing cholangitis
  3. In those with concomitant Inflammatory Bowel Disease, clinical and colonoscopic evidence, (in line with the patient's standard of care; within 18 months) of stable disease, without findings of high grade dysplasia
  4. In those on treatment with UDCA, therapy must be stable for at least 3 months, and at a dose not greater than 20 mg/kg/day. In those not on treatment with UDCA at the time of screening, a minimum of 8 weeks since the last dose of UDCA should be recorded
  5. Serum ALP greater than 1.5 x ULN
  6. Stable serum ALP levels (levels must not change by more than 25% from Screening Visit 1 and Screening Visit 2)
  7. Female subjects of childbearing potential must have a negative pregnancy test prior to starting trial treatment. For the purposes of this trial, a female subject of childbearing potential is a woman who has not had a hysterectomy, bilateral oophorectomy, or medically-documented ovarian failure. Women ≤ 50 years of age with amenorrhea of any duration will be considered to be of childbearing potential
  8. All sexually active women of childbearing potential must agree to use two forms of highly effective method of contraception from the Screening Visit throughout the trial period and for 99 days following the last dose of trial drug. If using hormonal agents the same method must have been used for at least 1 month before trial dosing and subjects must use a barrier method as the other form of contraception. Lactating women must agree to discontinue breast feeding before trial investigational medicinal product administration
  9. Men, if not vasectomised, must agree to use barrier contraception (condom plus spermicide) during heterosexual intercourse from screening through to trial completion and for 99 days from the last dose of trial investigational medicinal product
  10. Patients must weigh ≥ 40 kg

Exclusion Criteria:

  1. Presence of documented secondary sclerosing cholangitis on prior clinical investigations
  2. Presence of alternative causes of liver disease, that are considered by the Investigator to be the predominant active liver injury at the time of screening, including viral hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis. Patients with possible overlap syndrome with autoimmune hepatitis are excluded if the Investigator considers autoimmune hepatitis as the predominant liver injury
  3. AST and ALT >10 x ULN or bilirubin >3 x ULN or INR >1.3 in the absence of anti-coagulants
  4. Serum creatinine >130μmol/L or platelet count <50 x 109/L
  5. Any evidence of hepatic decompensation past or present, including ascites, episodes of hepatic encephalopathy or variceal bleeding
  6. Recent cholangitis within last 90 days or ongoing need for prophylactic antibiotics
  7. Pregnancy or breast feeding
  8. Harmful alcohol consumption as evaluated by the Investigator
  9. Flare in colitis activity within last 90 days requiring intensification of therapy beyond baseline maintenance treatment; use of oral prednisolone >10 mg/day, biologics (i.e. monoclonal antibodies) and or hospitalisation for colitis within 90 days. Prior use of biologics is not a contraindication to screening
  10. Diagnosed cholangiocarcinoma or high clinical suspicion of cholangiocarcinoma either clinically or by imaging
  11. Concurrent malignancies or invasive cancers diagnosed within past 3 years except for adequately treated basal cell and squamous cell carcinoma of the skin and in situ carcinoma of the uterine cervix
  12. Presence of a percutaneous drain or bile duct stent
  13. Major surgical procedure within 30 days of screening
  14. Prior organ transplantation
  15. Known hypersensitivity to the investigational product or any of its formulation excipients
  16. Unavailable for follow-up assessment or concern for subject's compliance
  17. Participation in an investigational trial of a drug or device within 60 days of screening or 5 half lives of the last dose of investigational drug, where the trial drug half-life is greater than 12 days
  18. Any other condition that in the opinion of the Investigator renders the subject a poor risk for inclusion into the trial
  19. Positive screening test for tuberculosis (TB) (including T-SPOT.TB TB test), unless respiratory review confirms false positive test results
  20. Receipt of live vaccination within 6 weeks prior to Screening Visit 2
  21. Known HIV positive status
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02239211
Other Study ID Numbers  ICMJE RG_13-027
2014-002393-37 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of Birmingham
Study Sponsor  ICMJE University of Birmingham
Collaborators  ICMJE
  • Biotie Therapies Corp.
  • University Hospital Birmingham
  • National Institute for Health Research, United Kingdom
Investigators  ICMJE
Principal Investigator: Philip Newsome, MD University of Birmingham
PRS Account University of Birmingham
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP